A student-run resource for reliable reports on the latest law and technology news

Archive for the ‘Pharmaceuticals’ Category

Federal Circuit Provides Guidance for Obviousness Determinations by the PTO and the Board of Patent Appeals and Interferences By Abby Lauer – Edited by Dorothy Du In re Kao, 2010-1307 (Fed. Cir. May 13, 2011) Slip Opinion The Federal Circuit vacated and remanded a decision of the Board of Patent Appeals and Interferences (“Board”), which had rejected patent application 11/680,432 (“the ‘432 application”) for obviousness. The Federal Circuit also affirmed findings of obviousness by the Board regarding patent applications 12/167,859 ... Read More...
Posted On May - 31 - 2011 Comments Off READ FULL POST
Written by Mehdi Eddebbarh & Jack Burns Edited by Albert Wang Editorial Policy I. Introduction Patent law strives to stimulate innovation by awarding inventors a temporary monopoly over patented inventions.  Antitrust law seeks to ensure efficient competition, in part by restricting monopolistic behavior.  Perhaps the most scrutinized area of intersection between patent law and antitrust law is the proper treatment of “reverse payments,” also referred to as “pay-for-delay” settlements.  Arkansas Carpenters Health and Welfare Fund v. Bayer AG, 625 F.3d ... Read More...
Posted On May - 13 - 2011 Comments Off READ FULL POST
Federal Circuit Rules Federal Law Trumps State Law in Interpretation of Patent Ownership Rights By Flora Amwayi – Edited by Jonathan Allred Abraxis Bioscience, Inc. v. Navinta LLC, 2009-1539, 2011 WL 873298 (Fed. Cir. Mar. 14, 2011) Slip Opinion The Federal Circuit denied a petition for an en banc rehearing of a Federal Circuit panel order dismissing Abraxis’ patent infringement case against Navinta. The court dismissed the case on the grounds that Abraxis did not have standing to sue for ... Read More...
Posted On Mar - 28 - 2011 Comments Off READ FULL POST
Federal Circuit Throws out $1.67 Billion Jury Verdict for Lack of Written Description Centocor Ortho Biotech, Inc. v. Abbott Lab., No. 2010-1144 (Fed. Cir. Feb. 23, 2011) By Katie Booth – Edited by Chinh Vo Slip Opinion The Federal Circuit recently ruled that a district court erred when it declined to grant the motion of defendant Abbott Laboratories (“Abbott”) for JMOL that the plaintiff’s asserted patent claims were invalid. In so holding, the court set aside a jury verdict of ... Read More...
Posted On Mar - 3 - 2011 Comments Off READ FULL POST
Federal Circuit rules that prosecution laches requires evidence of prejudice By Jonathan Allred – Edited by Elizabeth Akerman Cancer Research Technology Ltd. v. Barr Laboratories, Inc., No. 2010-1204 (Fed. Cir. Nov. 9, 2010) Slip Opinion The Federal Circuit overturned the District Court of Delaware, which had ruled that the plaintiff’s patent was unenforceable for prosecution laches, and, in the alternative, invalid for inequitable conduct. Prosecution laches is an equitable defense to infringement when the plaintiff has delayed the prosecution of ... Read More...
Posted On Nov - 17 - 2010 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
tech-042112-002-617x416

A Computer Programme

By Yaping Zhang – Edited by Jenny Choi On February 13, ...

Unknown

Flash Digest: News i

By Anne Woodworth Report Claims Facebook Privacy Policy in Violation of ...

Unknown

Federal Circuit Flas

By Amanda Liverzani PTO’s Statutory Interpretation on Patent Term Adjustment Upheld  In ...

Unknown

Alleged mastermind b

By Jens Frankenreiter – Edited by Katherine Kwong   U.S. v. ...

3293465641_b6c5081e87_q

Whack-a-troll Legisl

Written by: Asher Lowenstein Edited by: Yaping Zhang In May 2014, another ...